{"schema_version":"secwatch.filing_event.v1","accession":"0001295947-25-000027","form_type":"8-K","ticker":"PBH","cik":"0001295947","company_name":"Prestige Consumer Healthcare Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.606046+00:00","generated_at":"2026-05-17T17:11:03.592910+00:00","sec_items":["1.01","2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Prestige Q1 revenue down 6.6%, misses; acquires Pillar5 for CAD 150M, cuts FY26 outlook","bullets":["Revenue $249.5M (-6.6% YoY); diluted EPS $0.95 ($0.90 adjusted).","Clear Eyes supply constraints drove North American OTC revenue down to $212.6M.","Acquiring Pillar5 Pharma for CAD 150M cash; expected to close Q3 FY2026.","FY2026 outlook cut: revenue now $1.10-1.115B, EPS $4.50-4.58 (from $4.70-4.82).","Net debt ~$0.9B; leverage 2.4x; free cash flow guidance unchanged at $245M+."],"urls":{"canonical":"https://secwatch.observer/filing/0001295947-25-000027","json":"https://secwatch.observer/filing/0001295947-25-000027.json","markdown":"https://secwatch.observer/filing/0001295947-25-000027.md","text":"https://secwatch.observer/filing/0001295947-25-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1295947/000129594725000027/0001295947-25-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1295947/000129594725000027/pbh-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:11:03.592910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}